Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | -0.59% | +1.35% | +18.59% |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
May. 13 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.59% | 329B | B- | ||
+29.98% | 684B | C+ | ||
+30.34% | 568B | B | ||
-3.52% | 361B | C+ | ||
+4.07% | 284B | C+ | ||
+16.21% | 240B | B+ | ||
+9.66% | 208B | B- | ||
-6.83% | 200B | A+ | ||
+7.09% | 166B | C+ | ||
-1.22% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck & Co., Inc.